Who makes Dilaudid (hydromorphone) and who owns the brand? Dilaudid is a brand name for hydromorphone, an opioid pain medicine…. https://www.Drugchatter.com/chat/53035/who-owns-dilaudid-company/

What is the Chinese (CN) name for Ozempix? The provided information doesnt include any details about a product named… https://www.Drugchatter.com/chat/36985/ozempix-chinese-name/

Which Chinese pharmaceutical companies are investing in AI? A number of Chinese drugmakers have been putting money into… https://www.Drugchatter.com/chat/50765/chinese-pharmsutical-company-investing-in-ai/

Is Gleevec (imatinib) among the most expensive drugs? Gleevec (imatinib) is widely known as an expensive cancer medicine,… https://www.Drugchatter.com/chat/31710/is-gleevec-the-most-expensive-drug/

Branded Generics vs. Commodity Generics: How Brand Trust Wins Market Share
In generic drugs, the conversation is often framed as a race to the bottom: lowest price, fastest approvals, highest volume. But in the real worldwhere formularies tighten, phar…

Pharma has a timing problemand its getting more expensive.
In a world where launches are measured in weeks, not quarters, the patent first mindset is quickly shifting from legal strategy to commercial advantage. The core idea is simple: align IP filing…

Dont Get Blindsided: The Critical Drug Patent Mistakes That Can Sink M&A Due Diligence in Massachusetts
In life sciences M&A, the deal can look perfect on paperuntil a single patent detail turns a strategic acquisition into a costly scramble.
M…

Post-approval patents are supposed to be the aftercare of innovationextensions, tweaks, and new claims that keep therapies protected as they move from launch into real-world use. But for brand teams, generics counsel, and investors, theres a quieter st…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
The public conversation about drug exclusivity often starts and ends with a single number: 20 years. Its a clean headline. Its also a misleading shortcut.
In reality, the lengthand ev…